A young girl, infant 4 months old and young man showing a broad spectrum of young people
Bexsero: Help protect against a broad population¹

Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.1


Meningitis B awareness: Did you know?

2 of 3 parents are unaware that there is a separate vaccine against meningitis B.

Some parents believe that their child may have already been protected from meningitis B with just a meningococcal conjugate (MenACWY) vaccine.4,a

ᵃN=3600 parents and legal guardians from 8 countries (Australia, Brazil, Germany, Greece, Italy, Spain, UK, and USA) participated in a survey.

Common questions and answers with Bexsero

When your patients and their parents come to you with these common questions, Bexsero may be the answer.

Prescribing information (Great Britain) and (Northern Ireland)

Summary of product characteristics and patient information leaflet (Great Britain)

Summary of product characteristics and patient information leaflet (Northern Ireland)


  1. Bexsero Summary of Product Characteristics (Great Britain and Northern Ireland)
  2. Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–4245.
  3. Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
  4. GSK Data on file: 2017N320400_05.
  5. European Center for Disease Prevention and Control. Surveillance atlas of infectious diseases. https://atlas.ecdc.europa.eu/public/index.aspx Accessed December 2021

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline 0800 221 441

January 2022 | PM-GB-BEX-WCNT-200001 (V2.0)